Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

ClinicalTrials.gov ID: NCT01471028

Public ClinicalTrials.gov record NCT01471028. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) up to at least Study Day 91, with follow-up Protocol VTI-208E providing additional survival data up to a maximum of 5 years that will be included, as available, through VTI-208 study termination (after the last surviving enrolled subject completes Study Day 91). Secondary objectives are to determine the proportion of survivors at Study Days 28 and 91. Exploratory objectives are to evaluate the ability of ELAD to stabilize liver function, measured using the Model for End Stage Liver Disease (MELD)-based time to progression (TTP) up to Study Day 91, and the proportion of progression-free survivors (PFS) up to Study Days 28 and 91. Progression is defined as death or the first observed increase of at least 5 points from End of Study Day 1 MELD score (for both the ELAD and Control groups) until at least 24 hours after the ELAD Treatment Period is ended (end of Day 7 for Controls) and up to both End of Study Days 28 and 91 following Randomization.

Study identification

NCT ID
NCT01471028
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Vital Therapies, Inc.
Industry
Enrollment
203 participants

Conditions and interventions

Interventions

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2013
Primary completion
Dec 31, 2014
Completion
Jul 31, 2015
Last update posted
Feb 14, 2019

2013 – 2015

United States locations

U.S. sites
35
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
Maricopa Integrated Health System (MIHS) Phoenix Arizona 85008
University of Arizona Medical Center Tucson Arizona 85724
University of Arkansas for Medical Sciences Little Rock Arkansas 72205
Sharp Coronado Hospital Coronado California 92118
Keck Hospital of University of Southern California Los Angeles California 90033
Cedars-Sinai Medical Center Los Angeles California 90048
Stanford School of Medicine/Stanford University Medical Center Palo Alto California 94304
University of California San Diego Medical Center - Hillcrest San Diego California 92103
Georgetown University Hospital Washington D.C. District of Columbia 20007
University of Miami Hospital Miami Florida 33136
Tampa General Hospital Tampa Florida 33606
Cleveland Clinic Florida Weston Florida 33331
Piedmont Atlanta Hospital Atlanta Georgia 30309
Emory University Hospital Atlanta Georgia 30322
Rush University Medical Center Chicago Illinois 60612
Massachusetts General Hospital Boston Massachusetts 02114
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
University of Minnesota - Twin Cities Campus Minneapolis Minnesota 55455
University of Mississippi Medical Center Jackson Mississippi 39216
Rutgers University Hospital New Brunswick New Jersey 08903
North Shore University Hospital Manhasset New York 11030
New York University Langone Medical Center New York New York 10016
Columbia University Medical Center New York New York 10032
Montefiore Medical Center The Bronx New York 10467
Westchester Medical Center Valhalla New York 10595
Cleveland Clinic Foundation Cleveland Ohio 44195
Drexel University College of Medicine Philadelphia Pennsylvania 19102
Albert Einstein Medical Center Philadelphia Pennsylvania 19141
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15216
Methodist Dallas Medical Center Dallas Texas 75203
Baylor University Medical Center Dallas Texas 75246
The University of Texas Health Science Center - Texas Liver Institute San Antonio Texas 78215
University of Utah Hospital Salt Lake City Utah 84108
Swedish Medical Center - Transplant Program Seattle Washington 98104
University of Washington - Harborview Medical Center Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01471028, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 14, 2019 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01471028 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →